drugset / Trial / NCT05238311

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

NCT05238311 ↗

Expanded access No longer available Pfizer

Summary

Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Elranatamab Monoclonal antibody — —

Indications